Lv5
1136 积分 2023-06-27 加入
Preclinical characterization and phase 1 results of TQB2102, a first-in-class HER2 biparatopic antibody-drug conjugate, in patients with advanced solid tumors
12天前
已完结
Preclinical characterization and phase 1 results of TQB2102, a first-in-class HER2 biparatopic antibody-drug conjugate, in patients with advanced solid tumors
17天前
已完结
Clinical management, monitoring, and prophylaxis of adverse events of special interest associated with datopotamab deruxtecan
18天前
已完结
Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer: results from the TROPION-Breast01 China cohort
19天前
已完结
Capivasertib plus paclitaxel as first-line treatment for metastatic triple-negative breast cancer: results from the randomised, global phase III CAPItello-290 trial
19天前
已完结
Real-world outcomes of datopotamab deruxtecan after trastuzumab deruxtecan in hormone receptor–positive, HER2-negative metastatic breast cancer
26天前
已完结
Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial
26天前
已完结
Clinical management, monitoring, and prophylaxis of adverse events of special interest associated with datopotamab deruxtecan
26天前
已完结
Safety, Efficacy, and Pharmacokinetics of SHR-A1811, a Human Epidermal Growth Factor Receptor 2–Directed Antibody-Drug Conjugate, in Human Epidermal Growth Factor Receptor 2–Expressing or Mutated Advanced Solid Tumors: A Global Phase I Trial
1个月前
已完结
Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial
1个月前
已完结
皖公网安备34019202002308
